Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Exciting new results from a genetic study in humans and functional studies in mice have pinpointed interleukin 23 (IL23) and its receptor as a key pathway in the pathogenesis of inflammatory bowel disease (IBD). These findings reveal a hitherto unappreciated role for the IL23 axis in intestinal inflammation and may open new avenues for development of therapeutic strategies in IBD.

Original publication

DOI

10.1136/gut.2006.115402

Type

Journal article

Journal

Gut

Publication Date

10/2007

Volume

56

Pages

1333 - 1336

Keywords

Animals, Genetic Predisposition to Disease, Humans, Inflammatory Bowel Diseases, Interleukin-12, Interleukin-23, Mice, Receptors, Interleukin